Home LiteratureArticle Details
PMID: 15126781 Published · ppublish English Journal Article Multicenter Study

Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.

The Journal of urology ·Vol. 171 ·No. 6 Pt 1 ·2004-06-00 ·Pages 2181-5, quiz 2435

Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS

Abstract

We compared cancer specific survival of patients undergoing partial and radical nephrectomies for T1N0M0 renal tumors according to tumor size in a large multicenter series. A retrospective analysis of 1454 patients undergoing partial or radical nephrectomy for T1N0M0 renal tumors from 7 international academic centers was performed. Data were obtained for each patient including TNM stage (determined according to the 2002 TNM criteria), tumor size, type of surgery (partial versus radical nephrectomy) and cancer specific survival. Recurrence events were recorded when available. Partial and radical nephrectomies were performed in 379 (26.1%) and 1075 (73.9%) cases, respectively. Mean followup +/- SD was 62.5 +/- 51.8 months. Recurrence data were available on 544 patients. There were no significant differences in local or distant recurrence rates between patients undergoing partial or radical nephrectomy for either T1a (p = 0.6) or T1b tumors (p = 0.5). For patients with T1a tumors, there was no significant difference in the rate of cancer specific deaths between the partial (314) and radical (499) nephrectomy groups (2.2% versus 2.6%, respectively, p = 0.8). For patients with T1b tumors there was also no significant difference in the rate of cancer specific deaths between patients undergoing partial (65) and patients undergoing radical (576) nephrectomy (6.2% versus 9%, respectively, p = 0.6). Partial nephrectomy is becoming the gold standard for renal tumors less than 4 cm but this treatment is much more controversial for larger T1 tumors. This large multicenter study suggests that it is safe to expand the indications of partial nephrectomy to include patients with T1N0M0 tumors up to 7 cm. However, careful patient selection remains necessary.

MeSH Terms
Carcinoma, Renal Cell/mortality,pathology,surgery Female Follow-Up Studies Global Health Humans Kidney Neoplasms/mortality,pathology,surgery Male Middle Aged Neoplasm Staging Nephrectomy/adverse effects,methods Prognosis Retrospective Studies Survival Rate
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Patard Jean-Jacques
Department of Urology, University of California Los Angeles, Los Angeles, California 90095-1738, USA.
Shvarts Oleg
Lam John S
Pantuck Allan J
Kim Hyung L
Ficarra Vincenzo
Cindolo Luca
Han Ken-Ryu
De La Taille Alexandre
Tostain Jacques
Artibani Walter
Abbou Claude C
Lobel Bernard
Chopin Dominique K
Figlin Robert A
Mulders Peter F A
Belldegrun Arie S
Article Info
Journal
The Journal of urology
Abbr.
J Urol
ISSN
0022-5347
Published
2004-06-00
Pages
2181-5, quiz 2435
Language
English
Region
United States
NLM ID
0376374
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com